beyfortus sanofi - Search News

News

RSV, Merck and Sanofi

Merck Wins FDA Nod for RSV Antibody, Tees Up Challenge to Sanofi, AstraZeneca

Merck’s Enflonsia will go up against Sanofi and AstraZeneca’s Beyfortus, which the partners plan to ship out early in the third quarter.

CNBC on MSN · 1d

FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Seeking Alpha on MSN · 17h

Merck’s RSV shot for infants cleared in U.S., challenging Sanofi/Astra’s dominance

Merck (NYSE:MRK) has received FDA approval for Enflonsia, a prophylactic antibody therapy designed to protect infants from respiratory syncytial virus (RSV) in a market dominated by Beyfortus, a rival RSV preventive shot developed by Sanofi (NASDAQ:SNY) and AstraZeneca (NASDAQ:AZN).

11h

Sanofi (ENXTPA:SAN) Expands Beyfortus RSV Protection Production For Global Demand

Sanofi (ENXTPA:SAN) has recently announced it will begin shipping Beyfortus in early Q3 2025. This move aims to support healthcare providers ahead of the RSV season. Sanofi's commitment to increasing ...

Fierce Pharma1d

Feeling RSV heat from Merck, Sanofi lays out early supply plans for Beyfortus

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season

Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.

pharmaphorum1d

Sanofi starts shipping RSV drug early as rival nears market

Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical ...

Pharmabiz23h

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season: Paris Tuesday, June 10, 2025, 11:00 Hrs [IST] Sanofi is shipp ...

8hon MSN

Newly approved therapy could offer another option for protecting infants from RSV, a common infection that can be deadly

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

STAT15h

Pharmalittle: We’re reading about a Merck shot for RSV, a lawsuit over an Arkansas PBM law, and more

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results